Unveiling the Power of Gut Microbiome in Predicting Neoadjuvant Immunochemotherapy Responses in Esophageal Squamous Cell Carcinoma.

ABSTRACT: The role of the gut microbiome in enhancing the efficacy of anticancer treatments like chemotherapy and radiotherapy is well acknowledged. However, there is limited empirical evidence on its predictive capabilities for neoadjuvant immunochemotherapy (NICT) responses in esophageal squamous cell carcinoma (ESCC). Our study fills this gap by comprehensively analyzing the gut microbiome's influence on NICT outcomes. We analyzed 16S rRNA gene sequences from 136 fecal samples from 68 ESCC patients before and after NICT, along with 19 samples from healthy controls. After NICT, marked microbiome composition changes were noted, including a decrease in ESCC-associated pathogens and an increase in beneficial microbes such as Limosilactobacillus, Lacticaseibacillus, and Staphyl

SUBMITTER: Liu L 

PROVIDER: S-EPMC11562848 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature